mRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 27-34

  Hunt, Dirk A ^a   Lane, Hilary M ^b   Zygmont, Matthew E ^c   Dervan, Peter A ^b   Hennigar, Randolph A ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast cancer; Fatty acid synthase; Lipid metabolism; mRNA

Indexed keywords

FATTY ACID SYNTHASE; MALONYL COENZYME A; MESSENGER RNA; POLYADENYLIC ACID;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME METABOLISM; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; RNA DEGRADATION; RNA STABILITY; WESTERN BLOTTING;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL LINE, TUMOR; FATTY ACID SYNTHETASE COMPLEX; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLY A; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 33847674065     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Asturias FJ, Chadick JZ, Cheung IK, Stark H, Witkowski A, Joshi AK and Smith S: Structure and molecular organization of mammalian fatty acid synthase. Nature Struct Mol Biol 12: 225-232, 2000.
2. Witkowski A, Ghosal A, Joshi AK, Witkowska HE, Asturias FJ and Smith S: Head-to-head coiled arrangement of the subunits of the animal fatty acid synthase. Chem Biol 11: 1667-1676, 2004.
3. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, Korber E and Kolb HJ: Fatty-acid biosynthesis in man, a pathway of minor importance. Purification optimal assay conditions and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler 367: 905-912, 1986.
4. Letexier D, Pinteur C, Large V, Frering V and Beylot M: Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue. J Lipid Res 44: 2127-2134, 2003.
5. Diraison F, Yankah V, Letexier D, Dusserre E, Jones P and Beylot M: Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans. J Lipid Res 44: 846-853, 2003.
6. Martin AW, Corrigan GA, Lear SC, Kuhajda FP and Pasternack GR: The prognostic significance of expression of OA-519 in infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 19: 213, 1991.
7. Shurbaji MS, Kuhajda FP, Pasternack GP and Thurmond TS: Expression of oncoantigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathol 97: 686-691, 1992.
8. Epstein J, Carmichael M and Partin A: OA-519 (Fatty Acid Synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 45: 81-86, 1995.
9. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F and Soerensen FB: The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol 176: 343-352, 1995.
10. Alo PL, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1996.
11. Gansler TS, Hardman W, Hunt D, Schaffei S and Hennigar RA: Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Human Pathol 28: 686-692, 1997.
12. Milgraum LZ, Witters LA, Pasternack GR and Kuhajda FP: Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3: 2115-2120, 1997.
13. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP and Hamilton SR: Expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150: 201-208, 1997.
14. Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, Botti C, Serpieri DE and Di Tondo U: Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85: 35-40, 1999.
15. Visca P, Alo PL, Del Nonno F, Bottie C, Trombetta G, Marandino F, Filippi S, Di Tondo U and Donnorso RP: Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors and ras protein product in colorectal adenomas, carcinomas and adjacent nonneoplastic mucosa. Clin Cancer Res 5: 4111-4118, 1999.
16. Alo PL, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, Serpieri DE and Di Tondo U: Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 7: 1383-1388, 2000.
17. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC and Grizzle WE: The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 31: 1068-1073, 2000.
18. Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, Di Tondo U and Pizer ES: Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 116: 129-134, 2001.
19. Swinnen JV, Roskams T, Joniau S, Poppel HV, Oyen R, Baert L, Heyns W and Verhoeven G: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19-22, 2002.
20. Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G and Alo PL: Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 24: 4169-4173, 2004.
21. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR and Kurman RJ: Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 83: 528-537, 1998.
22. Krontiras H, Roye GD, Beenken SE, Myers RB, Mayo MS, Peters GE and Grizzle WE: Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue. Head & Neck 21: 325-329, 1999.
23. Gabrielson EW, Pinn ML, Testa JR and Kuhajda FP: Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 7: 153-157, 2001.
24. Nemoto T, Terashima S, Kogure M, Hoshino Y, Kusakabe T, Suzuki T and Gotoh M: Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia. Pathobiology 69: 297-303, 2001.
25. Kusakabe T, Nashimoto A, Honma K and Suzuki T: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 40: 71-79, 2002.
26. Camassei FD, Jenkner A, Rava L, Bosman C, Francalanci P, Donfrancesco A, Alo PL and Boldrini R: Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: an interinstitutional study. Med Pediatr Oncol 40: 302-308, 2003.
27. Innocenzi D, Alo PL, Balzani A, Sebastiani V, Silipo V, La Torre G, Ricciardi G, Bosman C and Calvieri Sl: Fatty acid synthase expression in melanoma. J Cutan Pathol 30: 23-28, 2003.
28. Takahiro T, Shinichi K and Toshimitsu S: Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9: 2204-2212, 2003.
29. Visca P, Sebastiani V, Pizer ES, Botti C, De Carli P, Filippi S, Monaco S and Alo PL: Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res 23: 335-339, 2003.
30. Kapur P, Rakheja D, Roy LC and Hoang MP: Fatty acid synthase expression in cutaneous melanocytic neoplasms. Modern Pathol 18: 1107-1112, 2005.
31. Kapur P, Selim MA, Roy LC, Yegappan M, Weinberg AG and Hoang MP: Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Modern Pathol 18: 197-204, 2005.
32. Thompson BJ, Stern A and Smith S: Purification and properties of fatty acid synthetase from a human breast cell line. Biochim Biophys Acta 662: 125-130, 1981.
33. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD and Pasternack GR: Fatty acid synthase: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci (USA) 91: 6379-6383, 1994.
34. Hennigar RA, Pochet M, Hunt DA, Lukacher AE, Venema VJ, Seal E and Marrero MB: Characterization of fatty acid synthase in cell lines derived from experimental mammary tumors. Biochim Biophys Acta 1392: 85-100, 1998.
35. Oskouian B: Overexpression of fatty acid synthase in SKBR3 breast cancer cell line is mediated via a transcriptional mechanism. Cancer Lett 149: 43-51, 2000.
36. Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY and Lin JK: Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J 3: 267-276, 2003.
37. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE and Kuhajda FP: Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747, 1996.
38. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA and Kuhajda FP: Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60: 213-218, 2000.
39. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL and Townsend CA: Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97: 3450-3454, 2000.
40. Thupari JN, Pinn ML and Kuhajda FP: Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Comm 285: 217-223, 2001.
41. Vergote D, Cren-Olive C, Chopin V, Toillon RA, Rolando C, Hondermarck H and Le Bourhis X: (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts. Breast Cancer Res Treat 76: 195-201, 2002.
42. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV and Kuhajda FP: Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 63: 7330-7337, 2003.
43. Menendez JA, Mehrni I, Verma VA, Teng PK and Lupu R: Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinogenesis 41: 164-178, 2004.
44. Menendez JA, Colomer R and Lupu R: Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol Rep 12: 411-422, 2004.
45. Liu B, Wang Y, Fillgrove KL and Anderson VE: Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol 49: 187-193, 2002.
46. McFadden JM, Medghalchi SM, Thupari JN, Pinn ML, Vadlamudi A, Miller KI, Kuhajda FP and Townsend CA: Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J Medicinal Chem 48: 946-961, 2005.
47. Brusselmans K, Vrolix R, Verhoeven G and Swinnen JV: Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 280: 5636-5645, 2005.
48. Li JN, Mahmoud MA, Han WF, Ripple M and Pizer ES: Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res 261: 159-165, 2000.
49. Yang YA, Han WF, Morin PJ, Chrest FJ and Pizer ES: Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279: 80-90, 2002.
50. Yang YA, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW and Pizer ES: Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282: 132-137, 2003.
51. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A and Testa JR: Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24: 3574-3582, 2005.
52. Menendez JA, Colomer R and Lupu R: Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Medical Hypoth 64: 342-349, 2005.
53. Chalbos D and Rochefort H: A 250-kilodalton cellular protein is induced by progestins in two human breast cancer cell lines MCF7 and T47D. Biochem Biophys Res Comm 121: 421-427, 1984.
54. Chalbos D, Westley B, May F, Alibert C and Rochefort H: Cloning of cDNA sequences of a progestin-regulated mRNA from MCF7 human breast cancer cells. Nucl Acids Res 14: 965-982, 1984.
55. Chalbos D, Chambon M, Ailhaud G and Rochefort H: Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262: 9923-9926, 1987.
56. Joyeux C, Rochefort H and Chalbos D: Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol Endocrinol 4: 681-686, 1989.
57. Chalbos D, Joyeux C, Galtier F and Rochefort H: Progestin-induced fatty acid synthetase in human mammary tumors: from molecular to clinical studies. J Steroid Biochem Biol 43: 223-228, 1992.
58. Stampfer MR and Yaswen P: Culture systems for study of human mammary pithelial cell proliferation, differentiation and transformation. Cancer Surveys 18: 7-34, 1993.
59. Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, New York, 1989.
60. Salles FJ and Strickland S: Rapid and sensitive analysis of mRNA polyadenylation states by PCR. PCR Meth Applications 4: 317-321, 1995.
61. Meyers S, Temme C and Wahke E: Messenger RNA turnover in eukaryotes: Pathways and enzymes. Crit Rev Biochem Mol Biol 39: 197-216, 2004.
62. Bernstein P and Ross J: Poly(A), poly(A) binding protein and the regulation of mRNA stability. TIBS 14: 373-377, 1989.
63. Gallie DR: The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev 5: 2109-2116, 1991.
64. Gallie DR and Tanguay R: Poly(A) binds to initiation factors and increases cap-dependent translation in vitro. J Biol Chem 269: 17166-17173, 1994.
65. Jacobson A and Peltz SW: Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem 65: 693-739, 1996.
66. Shah GN, Giddings SJ and Mooradian AD: Shortening of poly(A) tail of glucose transporter- one mRNA in experimental diabetes meliitus. Brain Res 745: 213-220, 1997.
67. Beckel-Mitchener AC, Miera A, Keller R and Perrone-Bizzozero NI: Poly(A) tail length-dependent stabilization of GAP-43 mRNA by the RNA-binding protein HuD. J Biol Chem 277: 27996-28002, 2002.
68. Semenkovich CF, Coleman T and Fiedorek FT: Human fatty acid synthase mRNA: tissue distribution, genetic mapping and kinetics of decay after glucose deprivation. J Lipid Res 36: 1507-1521, 1995.